Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Nonmyeloablative allogeneic stem-cell transplantation can induce sustained regression of metastatic renal-cell carcinoma in patients who have had no response to conventional immunotherapy, consistent with a graft-versus-tumor effect.
Graft-versus-leukemia reactions in allogeneic chimeras.
It is demonstrated that the GVL effect of DLT is most effective in chronic myelogenous leukemia (CML), whereas it is less pronounced in acute leukemia and myeloma, and new approaches for adoptive immune therapy of leukemia, which promise a better prognosis for these patients are being developed.
High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.
It is suggested that graft T(reg) content may predict for risk of GVHD after SCT, and the ratio of CD4(+)FOXP3(+) T cells to CD4 (+)CD25 (+)FO XP3(-) T cells was significantly reduced in patients with GV HD, suggesting diminished control of effector T cells.
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
CD19.CAR-VSTs display antitumor activity and, because their number may be increased in the presence of viral stimuli, earlier treatment post-HSCT (when lymphodepletion is greater and the incidence of viral infection is higher) or planned vaccination with viral antigens may enhance disease control.
Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.
It is the first demonstration that a combined PR1 and WT1 vaccine is immunogenic, and support further studies of combination immunization strategies in leukemia patients.
Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome.
It is concluded that flow cytometric immunophenotyping may help establish the diagnosis of MDS, especially when morphology and cytogenetics are indeterminate.
Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation.
Significant delayed donor erythropoiesis is common following major ABO-incompatible NST and associated with prolonged persistence of host antidonor isohemagglutinin levels and resolution of PRCA following NST.
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.
The results emphasize the importance of lineage-specific chimerism analysis to successfully manipulate engraftment after nonmyeloablative allogeneic PBSC transplantation.
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.
An increased number of T cells with apparent specificity for trisomy 8 cells is consistent with an autoimmune pathophysiology in trisomers of myelodysplastic syndrome.
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
The increased response in patients after SCT suggests a quantitative explanation for the greater effect of allogeneic stem cell transplantation (SCT) and derive from memory T cells and occur at low frequencies in healthy individuals and at higher frequencies in patients with CML.